12,429 Shares in Establishment Labs Holdings Inc. $ESTA Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 12,429 shares of the company’s stock, valued at approximately $1,067,000.

A number of other large investors have also added to or reduced their stakes in ESTA. Nantahala Capital Management LLC boosted its holdings in shares of Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after buying an additional 197,962 shares in the last quarter. BlackRock Inc. purchased a new stake in Establishment Labs during the second quarter valued at approximately $135,752,000. Bamco Inc. NY boosted its stake in Establishment Labs by 21.5% in the second quarter. Bamco Inc. NY now owns 907,537 shares of the company’s stock valued at $38,761,000 after acquiring an additional 160,755 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Establishment Labs by 117.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Finally, William Blair Investment Management LLC acquired a new position in shares of Establishment Labs during the second quarter worth $61,273,000. 72.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ESTA. TD Cowen boosted their target price on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a report on Thursday, August 6th. Needham & Company LLC boosted their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. Finally, Mizuho increased their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.25.

Establishment Labs Stock Performance

Shares of ESTA opened at $74.29 on Friday. The stock has a 50-day moving average of $83.45 and a two-hundred day moving average of $74.89. Establishment Labs Holdings Inc. has a one year low of $36.53 and a one year high of $97.59. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock has a market cap of $2.21 billion, a P/E ratio of -56.71 and a beta of 1.05.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.57) earnings per share. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -1.15 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.